Skip to main content
. 2017 Nov 2;4(5):ENEURO.0253-17.2017. doi: 10.1523/ENEURO.0253-17.2017

Table 1.

Body weight, basal CORT concentration, and GR expression (fold induction, standardized to the noMD group at PND26) in the dorsal hippocampus, ventromedial prefrontal cortex (vmPFC), and dorsal striatum of male rats at PND26, PND29, and PND90

noMD MD Condition
PND26
Body weight (BW in g) 59 ± 1 52 ± 1 t(78) = 6; p < 0.0001
Basal CORT (ng/ml) 57 ± 20 178 ± 45 t(22) = 5.7; p = 0.025
GR hippocampus 1.0 ± 0.3 1.0 ± 0.2 t(15) = 0.23; p = 0.140
GR vmPFC 1.0 ± 0.2 2.4 ± 0.6 t(13) = −2.2; p = 0.049
GR striatum 1.0 ± 0.2 1.8 ± 0.6 t(8) = 0.2; p = 0.749
PND29 noMD
VEH
noMD
MIF
MD
VEH
MD
MIF
Condition ×
treatment
Condition
(noMD vs MD)
Treatment
(VEH vs MIF)
Body weight (BW in g) 75 ± 2 72 ± 1 65 ± 1 64 ± 2 F(1,28) = 0.4; p = 0.532 F(1,28) = 47; p < 0.0001 F(1,28) = 1.9; p = 0.180
Basal CORT (ng/ml) 228 ± 60 122 ± 45 68 ± 34 115 ± 65 F(1,20) = 2; p = 0.172 F(1,20) = 2.4;p = 0.140 F(1,20) = 0.3; p = 0.593
GR hippocampus 1.2 ± 0.2 0.8 ± 0.1 1.1 ± 0.3 1.2 ± 0.2 F(1,27) = 1.5; p = 0.226 F(1,27) = 0.35 p = 0.560 F(1,27) = 0.41; p = 0.525
GR vmPFC 1.2 ± 0.3 1.9± 0.6 1.4 ± 0.4 1.1 ± 0.3 F(1,24) = 1; p = 0.322 F(1,24) = 0.4; p = 0.524 F(1,24) = 3.7; p = 0.545
GR striatum 1.6 ± 0.7 2.2 ± 0.8 1.3 ± 0.3 1.4 ± 0.5 F(1,20) = 0.2; p = 0.692 F(1,20) = 0.8; p = 0.370 F(1,20) = 0.3; p = 0.590
PND90 noMD
VEH
noMD
MIF
MD
VEH
MD
MIF
Condition ×
treatment
Condition
(noMD vs MD)
Treatment
(VEH vs MIF)
Body weight (BW in g) 329 ± 6 334 ± 6 333 ± 5 331 ± 8 F(1,29) = 1.3; p = 0.262 F(1,29) = 0.7; p = 0.415 F(1,29) = 0.8; p = 0.368
Basal CORT (ng/ml) 191 ± 60 206 ± 56 104 ± 21 118 ± 37 F(1,24) = 0.0; p = 0.991 F(1,24) = 3.6; p = 0.071 F(1,24) = 0.10; p = 0.753
GR hippocampus 1.4± 0.4 0.9 ± 0.3 1.4 ± 0.4 0.8 ± 0.2 F(1,26) = 0.3; p = 0.871 F(1,26) = 0.4; p = 0.834 F(1,26) = 3.2; p = 0.9
GR vmPFC 2.2 ± 0.9 1.2 ± 0.3 1.2 ± 0.3 1.3 ± 0.5 F(1,24) = 0.9; p = 0.350 F(1,24) = 0.6; p = 0.430 F(1,24) = 0.8; p = 0.375
GR striatum 1.1 ± 0.8 1.8 ± 1 1.3 ± 0.5 0.6 ± 0.2 F(1,19) = 1.1; p = 0.300 F(1,19) = 0.5; p = 0.505 F(1,19) = 0.0; p = 0.994

All animals had been subjected to 24-h MD at PND3 or control treatment. Half of the animals were treated with MIF through oral gavage twice daily on PND26–PND28; the other half received VEH. Data represent mean ± SEM; all groups n = 6–8 animals, except for body weight at PND26, which was determined for all animals.